Unprofitable Stores and the Risk of Impairment of Fixed Assets
First written in FY2016. 14 of 33 entries say "Mitigated", first in FY2020. Latest entry: FY2026.
Pharmarise Holdings moved to the "Worse" side of this theme in 2017, the same year as the typical company in this theme.
The whole theme swung hardest in 2024: 19 of 32 companies on the "Worse" side.
10 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「In the current consolidated fiscal year, the Group recognized an impairment loss of ¥48 million, compared with ¥184 million in the same period of the previous fiscal year.」
Although impairment losses were recognized for unprofitable stores and other operations, they declined to ¥48 million from ¥184 million in the previous fiscal year. - 2026-03-19MitigatedEarnings
「The dispensing pharmacy business and merchandise business recorded impairment losses of ¥13 million and ¥8 million, respectively. The impairment loss for the nine months ended in the third quarter of the current consolidated fiscal year was ¥22 million.」
Impairment losses decreased from ¥47 million in the same period of the previous year to ¥22 million. - FY2026-H1MitigatedAnnual report
「Impairment losses of ¥1 million and ¥2 million were recognized in the dispensing pharmacy and merchandise sales businesses, respectively. The impairment loss recognized during the current interim consolidated accounting period was ¥3 million.」
Although impairment losses related to unprofitable stores and other locations occurred, they decreased from ¥36 million in the same period of the previous fiscal year to ¥3 million. - FY2025MitigatedAnnual report
「Because the earnings originally anticipated could no longer be expected from the assets described above, their carrying amounts were reduced to the recoverable amounts, and the resulting ¥184 million reduction was recognized as an impairment loss.」
Impairment of unprofitable stores and goodwill continues, but impairment losses decreased from ¥257 million in the previous fiscal year to ¥184 million. - FY2025-H1WorsenedAnnual report
「Impairment losses of ¥21 million and ¥14 million were recognized in the dispensing pharmacy and merchandise sales businesses, respectively. The impairment loss recognized during the current interim consolidated accounting period was ¥36 million.」
An impairment loss of ¥36 million was recognized in the dispensing pharmacy and merchandise sales businesses, up from ¥16 million in the same period of the previous fiscal year. Impairment related to unprofitable stores and other locations also occurred during the interim period. - FY2024WorsenedAnnual report
「In the current consolidated fiscal year, the Group recognized an impairment loss of ¥257 million, compared with ¥244 million in the same period of the previous fiscal year.」
Impairment losses increased from ¥244 million in the previous fiscal year to ¥257 million, with impairment occurring on stores, offices, idle assets and goodwill. - FY2024-Q3MitigatedAnnual report
「An impairment loss of ¥16 million was recognized in the dispensing pharmacy business.」
Although an impairment loss occurred, it decreased from ¥46 million in the same period of the previous fiscal year to ¥16 million. - FY2024-Q2MitigatedAnnual report
「An impairment loss of ¥16 million was recognized in the dispensing pharmacy business. The impairment loss recognized during the cumulative second quarter of the current consolidated fiscal year was ¥16 million.」
Although an impairment loss occurred, it decreased from ¥36 million in the same period of the previous fiscal year to ¥16 million. - FY2023WorsenedAnnual report
「In the current consolidated fiscal year, the Group recognized an impairment loss of ¥244 million, compared with ¥200 million in the same period of the previous fiscal year.」
Impairment losses increased from ¥200 million in the previous fiscal year to ¥244 million, indicating increased full-year realized risk related to unprofitable stores and other locations. - FY2023-Q3MitigatedAnnual report
「An impairment loss of ¥46 million was recognized in the dispensing pharmacy business.」
An impairment loss of ¥46 million was recognized in the dispensing pharmacy business, down from the ¥52 million combined impairment loss in the dispensing pharmacy business and other businesses in the same period of the previous fiscal year. - FY2023-Q2MitigatedAnnual report
「An impairment loss of ¥36 million was recognized in the dispensing pharmacy business. The impairment loss recognized during the cumulative second quarter of the current consolidated fiscal year was ¥36 million.」
An impairment loss of ¥36 million was recognized in the dispensing pharmacy business, down from ¥42 million in the same period of the previous fiscal year. - FY2023-Q1MitigatedAnnual report
「Not applicable.」
No impairment loss on fixed assets was recognized in the segment information for the cumulative first quarter of the current consolidated fiscal year. - FY2022WorsenedAnnual report
「In the current consolidated fiscal year, the Group recognized an impairment loss of ¥200 million, compared with ¥51 million in the same period of the previous fiscal year.」
Impairment losses increased from ¥51 million in the previous fiscal year to ¥200 million. Impairment actually occurred on stores, offices and goodwill because the earnings originally anticipated could no longer be expected. - FY2022-Q3WorsenedAnnual report
「Impairment losses of ¥10 million and ¥42 million were recognized in the dispensing pharmacy business and other businesses, respectively. The impairment loss recognized during the cumulative third quarter of the current consolidated fiscal year was ¥52 million.」
Impairment losses arose in the dispensing pharmacy business and other businesses, totaling ¥52 million during the cumulative third quarter of the current fiscal year. This increased from ¥35 million in the same period of the previous fiscal year and ¥42 million in the previous cumulative quarter. - FY2022-Q2WorsenedAnnual report
「Impairment losses of ¥0 million and ¥42 million were recognized in the dispensing pharmacy business and other businesses, respectively. The impairment loss recognized during the cumulative second quarter of the current consolidated fiscal year was ¥42 million.」
Impairment losses increased from ¥34 million in the same period of the previous fiscal year to ¥42 million, all of which was recognized in other businesses this time. - FY2022-Q1MaterialisedAnnual report
「Impairment losses of ¥0 million and ¥42 million were recognized in the dispensing pharmacy business and other businesses, respectively.」
While no impairment loss was recognized in the same period of the previous fiscal year, an impairment loss of ¥42 million was recognized in other businesses during the current first quarter. - FY2021MitigatedAnnual report
「In the current consolidated fiscal year, the Group recognized an impairment loss of ¥51 million, compared with ¥114 million in the same period of the previous fiscal year.」
Impairment losses decreased from ¥114 million in the previous fiscal year to ¥51 million, but impairment related to stores and goodwill occurred. - FY2021-Q3MitigatedAnnual report
「Impairment losses of ¥27 million and ¥8 million were recognized in the dispensing pharmacy business and other businesses, respectively. The impairment loss recognized during the cumulative third quarter of the current consolidated fiscal year was ¥35 million.」
An impairment loss of ¥35 million arose, but this was down from ¥68 million in the same period of the previous fiscal year. - FY2021-Q2MitigatedAnnual report
「Impairment losses of ¥25 million and ¥8 million were recognized in the dispensing pharmacy business and other businesses, respectively. The impairment loss recognized during the cumulative second quarter of the current consolidated fiscal year was ¥34 million.」
An impairment loss of ¥34 million was recognized in the dispensing pharmacy business and other businesses, down from ¥63 million in the same period of the previous fiscal year. - FY2021-Q1MitigatedAnnual report
「Not applicable.」
During the cumulative first quarter of the current consolidated fiscal year, the ¥7 million impairment loss in the dispensing pharmacy business recognized in the same period of the previous fiscal year was not recognized. - FY2020MitigatedAnnual report
「In the current consolidated fiscal year, the Group recognized an impairment loss of ¥114 million, compared with ¥134 million in the same period of the previous fiscal year.」
Impairment losses decreased from ¥134 million in the previous fiscal year to ¥114 million, but impairment related to unprofitable stores and other locations continues to occur. - FY2020-Q3WorsenedAnnual report
「Impairment losses of ¥64 million and ¥3 million were recognized in the dispensing pharmacy and merchandise sales businesses, respectively. The impairment loss recognized during the cumulative third quarter of the current consolidated fiscal year was ¥68 million.」
Impairment losses arose in the dispensing pharmacy and merchandise sales businesses, totaling ¥68 million during the cumulative third quarter of the current fiscal year. This exceeded the ¥23 million recorded in the same period of the previous fiscal year. - FY2020-Q2WorsenedAnnual report
「Impairment losses of ¥59 million and ¥3 million were recognized in the dispensing pharmacy and merchandise sales businesses, respectively. The impairment loss recognized during the cumulative second quarter of the current consolidated fiscal year was ¥63 million.」
Impairment losses actually occurred in the dispensing pharmacy and merchandise sales businesses, totaling ¥63 million during the cumulative second quarter of the current fiscal year. This exceeded the ¥16 million recorded in the same period of the previous fiscal year. - FY2020-Q1MaterialisedAnnual report
「An impairment loss of ¥7 million was recognized in the dispensing pharmacy business.」
An impairment loss of ¥7 million was recognized in the dispensing pharmacy business, and impairment related to unprofitable stores and other locations continues to occur. - FY2019-Q3MaterialisedAnnual report
「Impairment losses of ¥18 million and ¥4 million were recognized in the dispensing pharmacy and merchandise sales businesses, respectively. The impairment loss recognized during the cumulative third quarter of the current consolidated fiscal year was ¥23 million.」
Impairment losses continued to arise in the dispensing pharmacy and merchandise sales businesses, with ¥23 million recognized during the cumulative third quarter. This was down from ¥165 million in the same period of the previous fiscal year. - FY2019-Q2MaterialisedAnnual report
「Impairment losses of ¥12 million and ¥4 million were recognized in the dispensing pharmacy and merchandise sales businesses, respectively. The impairment loss recognized during the cumulative second quarter of the current consolidated fiscal year was ¥16 million.」
Impairment losses continued to arise in the dispensing pharmacy and merchandise sales businesses, with ¥16 million recognized during the cumulative second quarter of the current fiscal year. - FY2018WorsenedAnnual report
「In the current consolidated fiscal year, operating profit at 薬ヒグチ＆ファーマライズ株式会社 fell below expectations due to delays in the recovery of earnings, and impairment was recognized to improve the soundness of the financial position. As a result, the Group recognized an impairment loss of ¥625 million in the current consolidated fiscal year, compared with ¥336 million in the previous fiscal year.」
Impairment losses increased from ¥336 million in the previous fiscal year to ¥625 million, with delays in the recovery of earnings, mainly in the merchandise sales business, cited as a factor. - FY2018-Q3WorsenedAnnual report
「Impairment losses of ¥107 million and ¥57 million were recognized in the dispensing pharmacy and merchandise sales businesses, respectively. The impairment loss recognized during the cumulative third quarter of the current consolidated fiscal year was ¥165 million.」
Impairment losses arose in the dispensing pharmacy and merchandise sales businesses, totaling ¥165 million during the cumulative third quarter of the current fiscal year. This exceeded the ¥150 million recorded in the same quarter of the previous fiscal year. - FY2018-Q2MaterialisedAnnual report
「Impairment losses of ¥49 million and ¥11 million were recognized in the dispensing pharmacy and merchandise sales businesses, respectively. The impairment loss recognized during the cumulative second quarter of the current consolidated fiscal year was ¥61 million.」
Impairment losses actually occurred in the dispensing pharmacy and merchandise sales businesses, totaling ¥61 million during the cumulative period of the current quarter. - FY2017WorsenedAnnual report
「In the current consolidated fiscal year, operating profit at 薬ヒグチ＆ファーマライズ株式会社 fell below expectations due to delays in the recovery of earnings, and impairment was recognized to improve the soundness of the financial position. As a result, the Group recognized an impairment loss of ¥336 million in the current consolidated fiscal year, compared with ¥149 million in the previous fiscal year.」
Impairment losses arose against a backdrop of delayed earnings recovery, increasing from ¥149 million in the previous fiscal year to ¥336 million. - FY2017-Q3WorsenedAnnual report
「In the merchandise sales segment, impairment losses were recognized on store assets. The impairment loss recognized during the cumulative third quarter of the current consolidated fiscal year was ¥101 million.」
Impairment of store assets actually occurred in the merchandise sales segment, with impairment losses of ¥101 million recognized in that segment and ¥143 million on a consolidated basis. - FY2017-Q2MaterialisedAnnual report
「Impairment loss 27」
During the cumulative second quarter of the current consolidated fiscal year, an impairment loss of ¥27 million was also recognized. Impairment losses related to unprofitable and temporarily closed stores and other locations continue to occur. - FY2016First statedAnnual report
「However, if these measures do not progress as expected, we may need to recognize additional impairment losses.」
The group recognized an impairment loss of ¥149.923 million during the fiscal year on temporarily closed stores and other assets, indicating that the risk materialized as an actual loss.